Guest Editorial: Warning Letters ? A Symptom?

Publication
Article
BioPharm InternationalBioPharm International-03-15-2002
Volume 15
Issue 3

by Steven S. Kuwahara, Titan Pharmaceuticals Numerous warning letters and consent decrees have revealed problems in coping with even simple parts of the GMPs.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Mike Schaefers Simtra BioPharma Solutions, Shiva Khalafpour MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany
Chris Hagan, SCIEX
Daniel Fischer, Tevard
Junevity Co-founder & CEO, John Hoekman, PhD
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.